Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Credit agrmnt [a]
Quarterly results
Flexion Therapeutics Inc (FLXN) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/19/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FLEXION THERAPEUTICS, INC.",
"BYLAWS OF FLEXION THERAPEUTICS, INC.",
"Supplemental Indenture”), between Flexion Therapeutics, Inc., a Delaware corporation , as issuer, and Wells Fargo Bank, National Association, a national banking association organized under the laws of the United States of America, as trustee , to the Indenture, dated as of May 2, 2017 (as supplemented or otherwise modified prior to the date hereof, the “Indenture"
10/12/2021 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...
Docs: "AGREEMENT AND PLAN OF MERGER by and among: FLEXION THERAPEUTICS, INC., PACIRA BIOSCIENCES, INC., and OYSTER ACQUISITION COMPANY INC.",
"TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement is entered into as of October 11, 2021, by and among Pacira BioSciences, Inc., a Delaware corporation , Oyster Acquisition Company Inc., a Delaware corporation and a wholly owned subsidiary of Parent , and [●] . Recitals A. Stockholder is a holder of record and the “beneficial owner” ) of certain shares of common stock of Flexion Therapeutics, Inc., a Delaware corporation . B. Parent, Purchaser and the Company are entering into an Agreement and Plan of Merger dated on or about the date hereof which provides, among other things, for Purchaser to commence a cash tender offer to acquire all of the outstanding shares of Company Common Stock, par value $0.001 per share, of the Company and following the consummation of the Offe...",
"Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management"
08/04/2021 8-K Investor presentation, Quarterly results
Docs: "Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights  ZILRETTA® net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarter  Net loss in Q2 2021 decreased by $10.4 million , as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA sales  Company extends estimated cash runway into 2023 by refinancing term loan  Flexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 million  Data for FX301 bunionectomy study and FX201 single ascending dose/expansion knee osteoarthritis study anticipated by year-end  Conference call to be held today at 4:30 pm",
"Q2 2021 Commercial Metrics Overview August 4, 2021 Exhibit 99.2"
07/12/2021 8-K Appointed a new director
06/25/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
04/05/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
11/19/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/04/2020 8-K Quarterly results
Docs: "Equity Distribution Agreement dated November 4, 2020, by and among Flexion Therapeutics, Inc., Goldman Sachs & Co. LLC, and Credit Suisse Securities (USA) LLC",
"Legal Opinion of Cooley LLP",
"Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights"
10/13/2020 8-K Quarterly results
08/19/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
07/20/2020 8-K Quarterly results
07/14/2020 8-K Quarterly results
06/11/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/21/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"Opinion of Cooley LLP",
"Flexion Therapeutics Announces Proposed Public Offering of Common Stock",
"Flexion Therapeutics Announces Pricing of Public Offering of Common Stock"
05/20/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm",
"Financial Statements and Supplementary Data"
05/19/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amendment 1 to Amended and Restated Credit and Security Agreement, by and among Flexion Therapeutics, Inc., Silicon Valley Bank as agent, MidCap Financial Trust, Flexpoint MCLS Holdings, LLC and the other lenders from time to time party thereto"
05/07/2020 8-K Quarterly results
04/01/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic"
03/12/2020 8-K Quarterly results
01/09/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA should not be considered safe for epidural or intrathecal administration. • Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration: Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use. • Hypersensitivity reactions: Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care if an anaphylactic reaction occurs. • Joint infection and damage: A marked increase in joint pain, joint swelling, restricted m..."
12/26/2019 8-K Quarterly results
12/10/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/07/2019 8-K Investor presentation, Quarterly results
Docs: "Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights",
"Presentation of Flexion Therapeutics, Inc."
08/06/2019 8-K Quarterly results
06/21/2019 8-K Submission of Matters to a Vote of Security Holders
05/08/2019 8-K Investor presentation, Quarterly results
Docs: "Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights",
"Presentation of Flexion Therapeutics, Inc."
02/28/2019 8-K Quarterly results
01/07/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy